Prudential Financial
ABUS icon

Prudential Financial’s Arbutus Biopharma ABUS Stock Holding History

Prudential Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
26,380
+3,070
+13% +$13.5K ﹤0.01% 2303
2026
Q1 		$105K Buy
+23,310
New +$102K ﹤0.01% 2228
2025
Q4 		– Sell
-18,255
Closed -$82.9K – 2211
2025
Q3 		$82.9K Hold
18,255
– – ﹤0.01% 2293
2025
Q2 		$56.4K Buy
18,255
+7,610
+71% +$25.3K ﹤0.01% 2334
2025
Q1 		$37.2K Buy
+10,645
New +$35.5K ﹤0.01% 2220
2024
Q3 		– Sell
-14,975
Closed -$46.3K – 2706
2024
Q2 		$46.3K Buy
14,975
+2,390
+19% +$7.17K ﹤0.01% 2619
2024
Q1 		$32.5K Hold
12,585
– – ﹤0.01% 2626
2023
Q4 		$31.5K Buy
12,585
+1,220
+11% +$2.39K ﹤0.01% 2591
2023
Q3 		$23.1K Hold
11,365
– – ﹤0.01% 2567
2023
Q2 		$26.1K Hold
11,365
– – ﹤0.01% 2591
2023
Q1 		$34.4K Sell
11,365
-81,900
-88% -$231K ﹤0.01% 2530
2022
Q4 		$217K Buy
93,265
+58,900
+171% +$141K ﹤0.01% 2376
2022
Q3 		$65K Buy
34,365
+125
+0.4% +$294 ﹤0.01% 2542
2022
Q2 		$93K Sell
34,240
-422,420
-93% -$1.08M ﹤0.01% 2535
2022
Q1 		$1.36M Buy
456,660
+51,300
+13% +$157K ﹤0.01% 1734
2021
Q4 		$1.58M Buy
+405,360
New +$1.57M ﹤0.01% 1649

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prudential Financial's ABUS Position: Q2 2026 in Review

Prudential Financial increased its Arbutus Biopharma (ABUS) stake by 13% in Q2 2026, buying an estimated $13.5K and bringing the position to 26,380 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

Prudential Financial first reported a position in ABUS in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.58M in Q4 2021. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Prudential Financial held 26,380 shares of Arbutus Biopharma worth $127K as of Q2 2026.
  • Prudential Financial bought 3,070 Arbutus Biopharma shares in Q2 2026, an estimated $13.5K.
  • Arbutus Biopharma made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2303 holding.
  • Prudential Financial first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 16 quarters since.
  • Prudential Financial's Arbutus Biopharma position peaked at $1.58M in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.